Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira
by Zacks Equity Research
The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
by Zacks Equity Research
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
How Pfizer (PFE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Stock Market News for Nov 18, 2019
by Zacks Equity Research
Benchmarks closed at record highs on Friday on U.S.-China trade deal hopes in spite of mixed economic data.
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Stock Market News For Oct 30, 2019
by Zacks Equity Research
Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Strong Q3 Earnings Data Deluge
by Zacks Equity Research
Strong Q3 Earnings Data Deluge
Q3 Earnings Bonanza: GM, MRK, MA & More
by Mark Vickery
GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.
Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
by Zacks Equity Research
Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 19.05% and 4.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Positive Earnings Results Push Equities to All-Time Highs
by David Borun
A slew of positive results buoys stocks as we head toward the October Fed meeting
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.45, marking a -0.03% move from the previous day.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.